246 related articles for article (PubMed ID: 30604513)
1. Vincristine and sirolimus in the treatment of kaposiform haemangioendothelioma.
Peng S; Yang K; Xu Z; Chen S; Ji Y
J Paediatr Child Health; 2019 Sep; 55(9):1119-1124. PubMed ID: 30604513
[TBL] [Abstract][Full Text] [Related]
2. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
5. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up.
Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2015 Apr; 62(4):577-80. PubMed ID: 25346262
[TBL] [Abstract][Full Text] [Related]
6. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
10. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
11. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
12. Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.
Harbers VEM; van der Salm N; Pegge SAH; van der Vleuten CJM; Verhoeven BH; Vrancken SLAG; Schultze Kool LJ; Fuijkschot J; Te Loo DMMWM
Br J Clin Pharmacol; 2022 Jun; 88(6):2769-2781. PubMed ID: 34957601
[TBL] [Abstract][Full Text] [Related]
13. Kaposiform hemangioendothelioma: current knowledge and future perspectives.
Ji Y; Chen S; Yang K; Xia C; Li L
Orphanet J Rare Dis; 2020 Feb; 15(1):39. PubMed ID: 32014025
[TBL] [Abstract][Full Text] [Related]
14. A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas.
Ying H; Qiao C; Yang X; Lin X
Pediatrics; 2018 Apr; 141(Suppl 5):S425-S429. PubMed ID: 29610165
[TBL] [Abstract][Full Text] [Related]
15. First Intracardiac Kaposiform Hemangioendothelioma in an Infant Resolved With Sirolimus: A Case Report.
Zaidi SJ; Shaik S; Agrawal C; Cossor W
J Pediatr Hematol Oncol; 2018 Oct; 40(7):536-540. PubMed ID: 30067556
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
Kai L; Wang Z; Yao W; Dong K; Xiao X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):471-6. PubMed ID: 24464150
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
[No Abstract] [Full Text] [Related]
18. NEWBORNS WITH KASABACH-MERRITT PHENOMENON-ASSOCIATED KAPOSIFORM HEMANGIOENDOTHELIOMA: A REPORT OF 6 CASES.
Benzar IM; Rebenkov SO; Levytskyi AF; Fedoniuk LY; Fomina LV; Sas LM; Stravskyy TY
Wiad Lek; 2020; 73(8):1785-1789. PubMed ID: 33055352
[TBL] [Abstract][Full Text] [Related]
19. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
20. Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study.
Borst AJ; Eng W; Griffin M; Ricci KW; Engel E; Adams DM; Dayneka J; Cohen-Cutler SJ; Andreoli SM; Wu MD; Wheeler AP; Heym KM; Crary SE; Nakano TA; Schulte RR; Setty BA; McLean TW; Pahl KS; Intzes S; Pateva I; Teitelbaum M; Zong Z; Li Y; Jeng MR
Pediatr Blood Cancer; 2024 Mar; 71(3):e30779. PubMed ID: 38073018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
